{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:19:50Z","timestamp":1784956790233,"version":"3.55.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Objective<\/jats:title><jats:p>To provide a summary of the economic and methodological evidence on capturing antimicrobial resistance (AMR) associated costs for curable sexually transmitted infections (STIs). To explore approaches for incorporating the cost of AMR within an economic model evaluating different treatment strategies for gonorrhoea, as a case study.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>A systematic review protocol was registered on PROSPERO (CRD42022298232). MEDLINE, EMBASE, CINAHL, Cochrane Library, International Health Technology Assessment Database, National Health Service Economic Evaluation Database, and EconLit databases were searched up to August 2022. Included studies were analysed, quality assessed and findings synthesised narratively. Additionally, an economic evaluation which incorporated AMR was undertaken using a decision tree model and primary data from a randomised clinical trial comparing gentamicin therapy with standard treatment (ceftriaxone). AMR was incorporated into the evaluation using three approaches\u2014integrating the additional costs of treating resistant infections, conducting a threshold analysis, and accounting for the societal cost of resistance for the antibiotic consumed.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Twelve studies were included in the systematic review with the majority focussed on AMR in gonorrhoea. The cost of ceftriaxone resistant gonorrhoea and the cost of ceftriaxone sparing strategies were significant and related to the direct medical costs from persistent gonorrhoea infections, sequelae of untreated infections, gonorrhoea attributable-HIV transmission and AMR testing. However, AMR definition, the collection and incorporation of AMR associated costs, and the perspectives adopted were inconsistent or limited. Using the review findings, different approaches were explored for incorporating AMR into an economic evaluation comparing gentamicin to ceftriaxone for gonorrhoea treatment. Although the initial analysis showed that ceftriaxone was the cheaper treatment, gentamicin became cost-neutral if the clinical efficacy of ceftriaxone reduced from 98% to 92%. By incorporating societal costs of antibiotic use, gentamicin became cost-neutral if the cost of ceftriaxone treatment increased from \u00a34.60 to \u00a38.44 per patient.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>Inclusion of AMR into economic evaluations may substantially influence estimates of cost-effectiveness and affect subsequent treatment recommendations for gonorrhoea and other STIs. However, robust data on the cost of AMR and a standardised approach for conducting economic evaluations for STI treatment which incorporate AMR are lacking, and requires further developmental research.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0292273","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T17:42:57Z","timestamp":1697737377000},"page":"e0292273","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-8949","authenticated-orcid":true,"given":"Oluseyi","family":"Ayinde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D. C.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"pone.0292273.ref001","first-page":"2021","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021","author":"WHO","year":"2021"},{"issue":"1","key":"pone.0292273.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz101","article-title":"Antimicrobial resistance in sexually transmitted infections.","volume":"27","author":"V Tien","year":"2020","journal-title":"J Travel Med."},{"issue":"3","key":"pone.0292273.ref003","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/infdis\/jis356","article-title":"Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy","volume":"206","author":"AC Sena","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0292273.ref004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.","volume":"27","author":"M Unemo","year":"2014","journal-title":"Clin Microbiol Rev."},{"issue":"11","key":"pone.0292273.ref005","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"M Unemo","year":"2021","journal-title":"Lancet Microbe"},{"issue":"3","key":"pone.0292273.ref006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"E Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0292273.ref007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1473-3099(11)70316-4","article-title":"The crisis of no new antibiotics\u2014what is the way forward?","volume":"12","author":"LJ Piddock","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0292273.ref008","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(21)00625-3","article-title":"Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.","volume":"22","author":"HJC de Vries","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0292273.ref009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmi.2019.08.004","article-title":"Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial","volume":"26","author":"F Rob","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"pone.0292273.ref010","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/ijerph10094274","article-title":"Strategies to minimize antibiotic resistance","volume":"10","author":"CR Lee","year":"2013","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"pone.0292273.ref011","doi-asserted-by":"crossref","first-page":"e015447","DOI":"10.1136\/bmjopen-2016-015447","article-title":"Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study","volume":"7","author":"KM Turner","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0292273.ref012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/OLQ.0000000000000698","article-title":"A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection.","volume":"45","author":"LT Allan-Blitz","year":"2018","journal-title":"Sex Transm Dis."},{"key":"pone.0292273.ref013","doi-asserted-by":"crossref","first-page":"f1493","DOI":"10.1136\/bmj.f1493","article-title":"The true cost of antimicrobial resistance","volume":"346","author":"R Smith","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"pone.0292273.ref014","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/antibiotics8040166","article-title":"Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance.","volume":"8","author":"EAF Holmes","year":"2019","journal-title":"Antibiotics (Basel)."},{"issue":"650","key":"pone.0292273.ref015","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.3399\/bjgp16X686533","article-title":"Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance.","volume":"66","author":"R Oppong","year":"2016","journal-title":"Br J Gen Pract"},{"issue":"1","key":"pone.0292273.ref016","first-page":"38","article-title":"Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies.","volume":"18","author":"M Jit","year":"2020","journal-title":"BMC Med.PubMed Central PMCID"},{"issue":"3","key":"pone.0292273.ref017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S","article-title":"Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?","volume":"5","author":"J Coast","year":"1996","journal-title":"Health Econ"},{"issue":"1","key":"pone.0292273.ref018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13756-018-0384-3","article-title":"Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.","volume":"7","author":"P Shrestha","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"pone.0292273.ref019","volume-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care:","author":"J Akers","year":"2009"},{"issue":"3","key":"pone.0292273.ref020","doi-asserted-by":"crossref","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"18","author":"MJ Page","year":"2021","journal-title":"PLoS Med."},{"issue":"1","key":"pone.0292273.ref021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1471-0528.2002.00223.x","article-title":"Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness.","volume":"109","author":"T Roberts","year":"2002","journal-title":"BJOG"},{"issue":"1","key":"pone.0292273.ref022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-11-80","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"11","author":"D Husereau","year":"2013","journal-title":"BMC Med."},{"issue":"08\/09","key":"pone.0292273.ref023","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1055\/s-0042-124664","article-title":"Checkliste zur Erstellung und Bewertung von Krankheitskostenstudien.","volume":"80","author":"D M\u00fcller","year":"2018","journal-title":"Gesundheitswesen."},{"issue":"10190","key":"pone.0292273.ref024","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.","volume":"393","author":"JDC Ross","year":"2019","journal-title":"Lancet"},{"key":"pone.0292273.ref025","author":"BNF","year":"2022","journal-title":"Drugs A to Z"},{"key":"pone.0292273.ref026","article-title":"Unit costs of health and social care 2021.","author":"K Jones","year":"2021","journal-title":"Kent: Personal Social Services Research Unit"},{"issue":"5","key":"pone.0292273.ref027","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.","volume":"32","author":"AH Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"10","key":"pone.0292273.ref028","first-page":"541","article-title":"Guideline Development Group British Association for Sexual Health and HIV","volume":"22","author":"C Bignell","year":"2011","journal-title":"UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS."},{"issue":"1","key":"pone.0292273.ref029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0956462419886775","article-title":"2018 UK national guideline for the management of infection with Neisseria gonorrhoeae","volume":"31","author":"H Fifer","year":"2020","journal-title":"Int J STD AIDS"},{"key":"pone.0292273.ref030","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2015"},{"issue":"3","key":"pone.0292273.ref031","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(89)90299-4","article-title":"Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal","volume":"86","author":"RS Phillips","year":"1989","journal-title":"Am J Med"},{"issue":"4","key":"pone.0292273.ref032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007435-199010000-00005","article-title":"Penicillin resistant Neisseria gonorrhoeae in low prevalence areas: implications for cost-effective management.","volume":"17","author":"MD Nettleman","year":"1990","journal-title":"Sex Transm Dis"},{"issue":"9","key":"pone.0292273.ref033","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1046\/j.1365-3156.2000.00616.x","article-title":"Cost-effectiveness of management strategies for acute urethritis in the developing world","volume":"5","author":"F Crabbe","year":"2000","journal-title":"Trop Med Int Health"},{"issue":"8","key":"pone.0292273.ref034","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3201\/eid1108.050157","article-title":"Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae","volume":"11","author":"K Roy","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pone.0292273.ref035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.qai.0000229014.39451.33","article-title":"The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi.","volume":"43","author":"MA Price","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0292273.ref036","author":"CDC","year":"2015","journal-title":"National action plan for combatting antibiotic resistance, March 2015"},{"issue":"9","key":"pone.0292273.ref037","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/OLQ.0000000000000480","article-title":"Cost-Effectiveness of Dual Antimicrobial Therapy for Gonococcal Infections Among Men Who Have Sex With Men in the Netherlands.","volume":"43","author":"M Xiridou","year":"2016","journal-title":"Sex Transm Dis."},{"issue":"4","key":"pone.0292273.ref038","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/OLQ.0000000000000725","article-title":"An Illustration of the Potential Health and Economic Benefits of Combating Antibiotic-Resistant Gonorrhea.","volume":"45","author":"HW Chesson","year":"2018","journal-title":"Sex Transm Dis"},{"issue":"43","key":"pone.0292273.ref039","article-title":"Antimicrobial resistance point-of-care testing for gonorrhoea treatment regimens: cost-effectiveness and impact on ceftriaxone use of five hypothetical strategies compared with standard care in England sexual health clinics.","volume":"25","author":"EM Harding-Esch","year":"2020","journal-title":"Euro Surveill."},{"issue":"2","key":"pone.0292273.ref040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/OLQ.0000000000001090","article-title":"Addressing Neisseria gonorrhoeae Treatment Resistance With the DNA Gyrase A Assay: An Economic Study, United States.","volume":"47","author":"A Wynn","year":"2020","journal-title":"Sex Transm Dis."},{"key":"pone.0292273.ref041","doi-asserted-by":"crossref","first-page":"956462420949126","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults.","author":"M Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"key":"pone.0292273.ref042","doi-asserted-by":"crossref","first-page":"114818","DOI":"10.1016\/j.socscimed.2022.114818","article-title":"Optimal subscription models to pay for antibiotics","volume":"298","author":"E Barlow","year":"2022","journal-title":"Social science & medicine (1982)."},{"issue":"1","key":"pone.0292273.ref043","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1057\/s41599-019-0263-4","article-title":"Current accounts of antimicrobial resistance: stabilisation, individualisation and antibiotics as infrastructure.","volume":"5","author":"CIR Chandler","year":"2019","journal-title":"Palgrave Commun."},{"key":"pone.0292273.ref044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/9781108864121.003","volume-title":"Challenges to Tackling Antimicrobial Resistance: Economic and Policy Responses. European Observatory on Health Systems and Policies","author":"D Ait Ouakrim","year":"2020"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:29:24Z","timestamp":1730352564000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292273"}},"subtitle":[],"editor":[{"given":"Kwame Kumi","family":"Asare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0292273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}